AC Immune, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative diseases listed on the Nasdaq completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per
Tags :Shu Zhang
Bär & Karrer advises Miele o the Establishment of a Joint Venture in the Fields of Infection Control and Life Science Miele and Metall Zug have reached an agreement outlining the establishment of a
Novartis has completed the spin-off of Sandoz‘s generics and biosimilars business, with the result that Sandoz Group debuted as an independent, publicly traded company. Sandoz shares were successfully listed on the Swiss stock exchange,
Credit Suisse and UBS signed a merger agreement, with UBS emerging as the surviving entity. With the combined market capitalization is approximately USD 65 billion, the merger follows negotiations between the two Swiss banks, prompted by
Cavotec has successfully placed 12,452,830 shares at a subscription price of SEK 13.25 per share, entailing raising proceeds of approximately SEK 165 million. The subscription price was determined through an accelerated book building procedure conducted by Skandinaviska
Cavotec has successfully carried out a directed share issue, with the guidance and legal assistance of Bär & Karrer. The share placement involved 12,452,830 shares sold at a subscription price of SEK 13.25 per share, resulting
